Literature DB >> 31904361

In vitro response and gene expression of human retinal Müller cells treated with different anti-VEGF drugs.

Javier Cáceres-Del-Carpio1, M Tarek Moustafa1, Jaime Toledo-Corral1, Mohamed A Hamid1, Shari R Atilano1, Kevin Schneider1, Paula S Fukuhara1, Rodrigo Donato Costa1, J Lucas Norman1, Deepika Malik1, Marilyn Chwa1, David S Boyer2, G Astrid Limb3, M Cristina Kenney4, Baruch D Kuppermann5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31904361      PMCID： PMC7058176          DOI： 10.1016/j.exer.2019.107903

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN： 0014-4835            Impact factor:   3.467


× No keyword cloud information.
  54 in total

1.  Glial cell factors and the outer blood retinal barrier.

Authors:  Paul A Constable; John G Lawrenson
Journal:  Ophthalmic Physiol Opt       Date:  2009-09       Impact factor: 3.117

Review 2.  New functions of Müller cells.

Authors:  Andreas Reichenbach; Andreas Bringmann
Journal:  Glia       Date:  2013-02-26       Impact factor: 7.452

3.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Authors:  David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi
Journal:  Ophthalmology       Date:  2010-04-09       Impact factor: 12.079

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Authors:  Daniel F Martin; Maureen G Maguire; Stuart L Fine; Gui-shuang Ying; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Maryann Redford; Frederick L Ferris
Journal:  Ophthalmology       Date:  2012-05-01       Impact factor: 12.079

7.  Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.

Authors:  Sven Schnichels; Ulrike Hagemann; Kai Januschowski; Johanna Hofmann; Karl-Ulrich Bartz-Schmidt; Peter Szurman; Martin S Spitzer; Sabine Aisenbrey
Journal:  Br J Ophthalmol       Date:  2013-05-17       Impact factor: 4.638

Review 8.  Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact.

Authors:  Sumit Randhir Singh; Avantika Dogra; Michael Stewart; Taraprasad Das; Jay Chhablani
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2017-10-03

Review 9.  An overview of the involvement of interleukin-18 in degenerative retinopathies.

Authors:  Matthew Campbell; Sarah L Doyle; Ema Ozaki; Paul F Kenna; Anna-Sophia Kiang; Marian M Humphries; Peter Humphries
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

10.  Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.

Authors:  Deepika Malik; Mohamed Tarek; Javier Caceres del Carpio; Claudio Ramirez; David Boyer; M Cristina Kenney; Baruch D Kuppermann
Journal:  Br J Ophthalmol       Date:  2014-06       Impact factor: 4.638
View more
  4 in total

1.  Effect of intravitreal ranibizumab on fibrovascular membranes in patients with proliferative diabetic retinopathy.

Authors:  Ze-Yu Liang; Yi-Peng Wang; Jing Li; Wen-Chao Yang; Yong-Fang Tu; Yue Zhang; Song Chen
Journal:  Int J Ophthalmol       Date:  2022-10-18       Impact factor: 1.645

2.  Differential effects of risuteganib and bevacizumab on AMD cybrid cells.

Authors:  Kevin Schneider; Marilyn Chwa; Shari R Atilano; Zixuan Shao; John Park; Hampar Karageozian; Vicken Karageozian; M Cristina Kenney
Journal:  Exp Eye Res       Date:  2020-10-16       Impact factor: 3.770

3.  VEGF-Independent Activation of Müller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients.

Authors:  Sara Rezzola; Jessica Guerra; Adwaid Manu Krishna Chandran; Alessandra Loda; Anna Cancarini; Piergiuseppe Sacristani; Francesco Semeraro; Marco Presta
Journal:  Int J Mol Sci       Date:  2021-02-22       Impact factor: 5.923

4.  Oxidative Stress Induces a VEGF Autocrine Loop in the Retina: Relevance for Diabetic Retinopathy.

Authors:  Maria Grazia Rossino; Matteo Lulli; Rosario Amato; Maurizio Cammalleri; Massimo Dal Monte; Giovanni Casini
Journal:  Cells       Date:  2020-06-11       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.